Scientists have successfully developed a new drug treatment for children with brain cancer using artificial intelligence, according to a recent report in Britain. The survival rate of children with this brain cancer has not improved in the past half century. Experts said that this breakthrough will open a new era: using artificial intelligence to develop new cancer therapies. The method is published in the journal Cancer discovery.
Professor Kristian Helin, chief executive officer of Cancer Research Institute in London, UK, believes that according to the findings of the Research Institute’s team of scientists, doctors and data analysts, “artificial intelligence is expected to have a transformative impact on new drug research and development.” he believes that in this study, artificial intelligence can be used to confirm whether the drug combination is expected to treat previously incurable brain cancer children in the future. This breakthrough will be the first case where artificial intelligence will be used for treatment and benefit patients.
Computer scientists and cancer experts at the Cancer Institute in London and the Royal Marsden NHS Foundation Trust used artificial intelligence to come to the conclusion that everolimus and vandetanil were combined to treat diffuse pontine glioma (DIPG). This is a rare and fast-growing brain tumor in children.
At present, DIPG and other similar tumors are difficult to be surgically removed because they are diffuse, which means that there is no clear boundary for surgery. However, after analyzing the data of existing drugs, the research team found that everolimus could enhance the ability of vandetanil to cross the blood-brain barrier and treat cancer.
The efficacy of this drug combination has been confirmed in mice and is now tested in children. Experts hope to test a larger group of children in clinical trials. The study found that the combination of the two drugs could improve the survival rate of experimental mice by 14% compared with experimental mice receiving traditional treatment.
Chris Jones, a professor of pediatric brain tumor biology at the international cancer research center, said that DIPG is a rare and invasive brain cancer in children. The survival rate has been very low and has not improved in the past 50 years, so there is an urgent need to find new therapies.
He said that in terms of new drug combinations, people have no intuitive feeling about the impact of artificial intelligence on the discovery of cancer drugs such as DIPG. Comprehensive clinical trials are still needed to assess whether this treatment can be used in children, but the research results are faster than ever before AI.